Abbvie Inc
BMV:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
BMV:ABBV
Watchlist
Price: 3 810 MXN 0.08% Market Closed
Market Cap: Mex$346.3B

Operating Margin

33.1%
Current
Improving
by 1.5%
vs 3-y average of 31.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
33.1%
=
Operating Income
$19.7B
/
Revenue
$59.6B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
33.1%
=
Operating Income
Mex$19.7B
/
Revenue
$59.6B

Peer Comparison

Country Company Market Cap Operating
Margin
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Merck & Co Inc
NYSE:MRK
267.6B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.1B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
111.6B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...

Market Distribution

Higher than 92% of companies in the United States of America
Percentile
92st
Based on 14 112 companies
92st percentile
33.1%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Abbvie Inc
Glance View

AbbVie Inc., a leader in the pharmaceutical industry, emerged from its parent company Abbott Laboratories in 2013, with a mission centered around addressing some of the world’s most complex and serious diseases. At its core, AbbVie is a research-driven entity that leverages scientific innovation to develop advanced therapies. With a robust pipeline, the company focuses on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, and women's health. It has developed a diversified portfolio designed to tackle challenging health issues. The company devotes significant resources to research and development, fostering a culture that celebrates scientific discovery as a pathway to improving patient lives worldwide. Revenue generation for AbbVie is deeply intertwined with its treatment offerings, particularly its lineup of blockbuster drugs. The flagship product, Humira, an anti-inflammatory medication, has consistently stood as one of the top-selling drugs globally. Despite facing patent expirations for Humira, AbbVie has strategically navigated this challenge through its robust product pipeline, which includes promising medicines like Skyrizi and Rinvoq in immunology. The company also expanded its revenue potential significantly with the acquisition of Allergan in 2020, adding Botox and other products in aesthetics and eye care to its portfolio. The calculated diversification of revenue streams ensures AbbVie maintains a competitive edge, securing its position as a formidable player in the pharmaceutical industry.

ABBV Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
33.1%
=
Operating Income
$19.7B
/
Revenue
$59.6B
What is Abbvie Inc's current Operating Margin?

The current Operating Margin for Abbvie Inc is 33.1%, which is above its 3-year median of 31.5%.

How has Operating Margin changed over time?

Over the last 3 years, Abbvie Inc’s Operating Margin has decreased from 34.2% to 33.1%. During this period, it reached a low of 27.9% on Sep 30, 2024 and a high of 35.6% on Jun 30, 2023.

Back to Top